Exogene

Exogene is a private, preclinical-stage biotechnology company applying a proprietary generative AI platform to the discovery of novel T-cell receptor (TCR) therapies for solid tumors. The company has assembled a deeply technical team with expertise in machine learning, computational biology, immunology, and drug development to build its discovery engine and advance its internal pipeline. Operating as a platform company, Exogene aims to generate its own therapeutic assets while potentially leveraging its technology through partnerships to address the significant challenge of identifying safe, effective TCRs for cancer immunotherapy.

A generative AI and deep learning platform designed to mine the TCR sequence space to discover novel, high-affinity, and specific T-cell receptors (TCRs) against shared cancer targets for the development of off-the-shelf TCR-based therapies.

Exogene competes in the crowded AI-driven drug discovery space, facing competition from other biotech startups applying AI to protein design (e.g., Absci, Generate Biomedicines) and immuno-oncology specifically, as well as internal efforts at large pharma. Its narrow focus on TCR discovery for shared solid tumor targets is a differentiating, but high-difficulty, niche.